Biosimilar Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Biosimilar Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global biosimilar insulin market achieved a remarkable revenue milestone, reaching US$ 1.8 Bn by the end of 2024. A recent study conducted by Fairfield Market Research predicts an impressive compound annual growth, propelling the market to an estimated value of US$ 5 Bn by the close of 2031.

Dominating the Market: Biosimilar Insulin Sales

In 2023, biosimilar insulin sales gained significant traction within the global insulin market, underscoring their increasing relevance in meeting the requirements of diabetic patients worldwide. Fairfield Market Research data highlights this notable shift in the healthcare landscape.

Unlocking Growth for Biosimilar Insulin Product Manufacturers

""Cost-Effective Biosimilar Insulin – Meeting the Demand""

Access to affordable insulin has become a pressing issue, particularly for individuals in the low-income bracket. Recent efforts have been made in various jurisdictions and by commercial insurance companies to cap the price of insulin.

In February 2021, New York Senator Chuck Schumer introduced legislation to limit the cost of insulin for most diabetic patients to US$ 35. This issue gained further attention during the State of the Union address in March 2021 when U.S. President Biden supported the insulin price cap and advocated for Medicare to negotiate lower prescription drug prices.

Companies such as Biocon, Eli Lilly and Company, Sanofi, BGP Pharma, Aspen, and Mylan (Viatris) are developing biosimilar insulin to address this critical need.

In March 2022, a collaboration between JDRF and Civica aimed to produce low-cost biosimilar insulin, with prices expected to be no more than US$ 30 per vial and US$ 55 per box of five pen cartridges. Such collaborations are anticipated to drive high adoption rates and market growth.

R&D Investments and Technological Advancements

Manufacturers are also allocating funds to research and development, with the aim of introducing more cost-effective and advanced technologies in the field of biosimilar insulin. Increased research efforts are expected to result in the introduction of new technologies, further enhancing the acceptance and utilization of biosimilar insulin, ultimately leading to market expansion in the coming years.

Challenges in the Biosimilar Insulin Market

""Competitive Pressure and Price Reductions""

While the pharmaceutical industry is experiencing exponential growth through the introduction of novel products, biosimilar insulin products must adhere to stringent regulatory requirements to ensure product integrity.

Competition may drive pharmaceutical companies to reduce the prices of standard drugs. This competitive pressure could impact the demand for biosimilar insulin, making it crucial for biosimilar products to match the efficiency and reliability of standard drugs.

Regional Insights

U.S.: Leading the Way in Biosimilar Insulin

The prominence of the U.S. biosimilar insulin market can be attributed to the increasing number of FDA approvals for drugs that require cold storage. In 2023, the U.S. held a significant market share, and this trend is expected to continue. The approval of interchangeable biosimilars like Semglee, which can be substituted for reference products without clinician approval, has driven demand for biosimilar insulin in the U.S., thereby increasing the market's overall value.

U.K.: Leveraging Biosimilar Insulin for Healthcare Savings

The U.K. also has a substantial market share in the European biosimilar insulin market. The country's biopharma industry plays a crucial role in driving the demand for biosimilar insulin. While the U.K. offers several biosimilar insulin products, they must be prescribed by brand name and are not interchangeable. The cost-effectiveness of biosimilar insulin products presents opportunities for the National Health Service (NHS) to improve availability and manage healthcare costs.

India: A Booming Market for Biosimilar Insulin

India has emerged as a prominent market for biosimilar insulin, particularly in the Asia-Pacific (APAC) region. The Indian government is actively promoting the expansion of the biopharmaceutical industry to achieve self-sufficiency. Investment in biotechnology research and development has been a priority, with significant financial commitments. Over 100 Indian biopharmaceutical companies are involved in the production and marketing of biosimilars. These companies are modernizing their technology and workforce capabilities to tap into India's vast potential in this sector.

Competitive Analysis

Leading manufacturers are strategically lowering the prices of biosimilar insulin products to expand their market presence. Licensing, approvals, and corporate partnerships are key trends observed in the market, as companies seek to advance biosimilar insulin products.

Key Companies Profiled
• Biocon
• Eli Lilly and Company
• Sanofi
• BGP Pharma
• Aspen
• Mylan (Viatris)

Key Segments Covered in Biosimilar Insulin Industry Research

Biosimilar Insulin Market by Product:
• Insulin Glargine
• Insulin Analog
• Others

Biosimilar Insulin Market by Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Biosimilar Insulin Market by Region:
• North America Biosimilar Insulin Market
• Latin America Biosimilar Insulin Market
• Europe Biosimilar Insulin Market
• APAC Biosimilar Insulin Market
• Middle East & Africa Biosimilar Insulin Market

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.